Pharma Manufacturing

Recent site upgrades, acquisitions, and new partnerships demonstrate a shift from cost-driven outsourcing to integrated, locally anchored models, says the firm.

The company is investing approximately $108 million in a new drug product facility in Vancouver, Canada, and $100 million to modernize its Indiana API manufacturing site.

Five teams will create automated platforms capable of producing RNA-based genetic medicines and performing quality control testing at or near the point of care.

The drugmakers pledged to invest $19.6 billion collectively in U.S. manufacturing and provide discounts on select medicines in exchange for tariff exemptions.

Bioreactor automation and control systems grow to 38.6% adoption or planned implementation, finds 2026 annual report and survey by BioPlan Associates.

The CDMO plans to allocate most of offering proceeds toward its PolyPeptide Group acquisition, with the remaining funds slated for Bio Campus II investment.

The Chinese CRDMO is boosting manufacturing capacity globally through continued investments in China, Singapore, and the United States.

Scheduled to tour the company's flagship "smart factory" in Bridgewater this week, it was called off after losing Bristol Myers Squibb as a customer.

The loss is forcing the automated cell therapy manufacturer to resize, despite doubling the number of customers in 2026.

The increase was primarily attributable to growth in the CRDMO's number of customers and projects, driven by antibody-drug conjugates and the broader bioconjugate market.